Pharma-connected shares traded higher after US President Donald Trump imposed a 27 % reciprocal tariff’ on India, exempting pharmaceutical goods. Nifty Pharma jumped 4.9 % to the day’s high of 21,996.6. Around 9:37 AM, all 20 Nifty Pharma constituents traded in the inexperienced.
Nifty Pharma Companies Take Jumps In Stock
Among others, Gland Pharma was up 7.74 %, Lupin was up over 6.29 %, Aurobindo Pharma became up 5.9 %, Sun Pharma became up 5.4 %, and Natco Pharma was up 5 %. Similarly, Divi’s Laboratories was up 4.5 %, Dr. Reddy’s Laboratories was up 4.46 %, Zydus Lifesciences was up 4.18 %, and Ipca Laboratories was up 4.05 %.
As per records, some goods will not be challenge to the Reciprocal Tariff. These consist of: (1) articles subject to 50 USC 1702(b); (2) steel/aluminum articles and autos/car parts already subject to Section 232 tariffs; (3) copper, pharmaceuticals, semiconductors, and lumber articles; (4) all articles that could become challenge to future Section 232 price lists; (5) bullion; and (6) energy and other minerals that aren’t available in US.
Pharma Sector exempts from Trump Tariffs
“According to The Wall Street Journal on April 2, the Nifty Pharma zone excluded from the price lists introduced by the Trump management. While it is doubtful whether that is a short-time period or average-term association, we view it as positive for the world if pharmaceuticals were not targeted through tariffs,” mentioned in its notice.
Echoing a similar view, Anirudh Garg, associate and fund supervisor, Invasset PMS, stated, “Pharma exclusion in tariff is a primary remedy, considering that Indian pharma components over 40 % of the US’ general drug demand.”
Read Also: 49-storey ‘Ghost Tower’ in Bangkok went viral after 7.7-magnitude earthquake